Literature DB >> 30389404

Epithelial-mesenchymal transition: Initiation by cues from chronic inflammatory tumor microenvironment and termination by anti-inflammatory compounds and specialized pro-resolving lipids.

Chang Hoon Lee1.   

Abstract

Epithelial mesenchymal transition (EMT) is a biological process that plays a critical role in cancer progression. Blocking the process of EMT can be an essential strategy in the development of anticancer drugs. In this paper, we briefly introduce recent research trends and issues of EMT, focusing on the relationship of EMT with the entire cycle of inflammation (from initiation to resolution of inflammation). Recent findings on the relationship between EMT and immune evasion are discussed. We will also explore the importance of controlling inflammation by anti-inflammatory compounds and specialized pro-resolving lipids to inhibit EMT process in cancer.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anti-inflammatory compounds; Epithelial mesenchymal transition; Immune evasion; Inflammation; Pro-resolving specialized lipids

Mesh:

Substances:

Year:  2018        PMID: 30389404     DOI: 10.1016/j.bcp.2018.10.031

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  12 in total

1.  TGF-β promote epithelial-mesenchymal transition via NF-κB/NOX4/ROS signal pathway in lung cancer cells.

Authors:  Mingze Ma; Fengxian Shi; Ruonan Zhai; Hang Wang; Ke Li; Chunyan Xu; Wu Yao; Fang Zhou
Journal:  Mol Biol Rep       Date:  2021-04-01       Impact factor: 2.316

2.  PRR16/Largen Induces Epithelial-Mesenchymal Transition through the Interaction with ABI2 Leading to the Activation of ABL1 Kinase.

Authors:  Gyeoung Jin Kang; Jung Ho Park; Hyun Ji Kim; Eun Ji Kim; Boram Kim; Hyun Jung Byun; Lu Yu; Tuan Minh Nguyen; Thi Ha Nguyen; Kyung Sung Kim; Hiệu Phùng Huy; Mostafizur Rahman; Ye Hyeon Kim; Ji Yun Jang; Mi Kyung Park; Ho Lee; Chang Ick Choi; Kyeong Lee; Hyo Kyung Han; Jungsook Cho; Seung Bae Rho; Chang Hoon Lee
Journal:  Biomol Ther (Seoul)       Date:  2022-06-20       Impact factor: 4.231

3.  Snail Promotes Cancer Cell Proliferation via Its Interaction with the BIRC3.

Authors:  Seung Bae Rho; Hyun-Jung Byun; Boh-Ram Kim; Chang Hoon Lee
Journal:  Biomol Ther (Seoul)       Date:  2022-06-17       Impact factor: 4.231

4.  4,5-Diaryl 3(2H)Furanones: Anti-Inflammatory Activity and Influence on Cancer Growth.

Authors:  Dmitrii Semenok; Jury Medvedev; Lefki-P Giassafaki; Iason Lavdas; Ioannis S Vizirianakis; Phaedra Eleftheriou; Antonis Gavalas; Anthi Petrou; Athina Geronikaki
Journal:  Molecules       Date:  2019-05-06       Impact factor: 4.411

5.  YDJC Induces Epithelial-Mesenchymal Transition via Escaping from Interaction with CDC16 through Ubiquitination of PP2A.

Authors:  Eun Ji Kim; Mi Kyung Park; Gyeoung-Jin Kang; Hyun Jung Byun; Hyun Ji Kim; Lu Yu; Boram Kim; Hee-Sung Chae; Young-Won Chin; Jae Gal Shim; Ho Lee; Chang Hoon Lee
Journal:  J Oncol       Date:  2019-08-07       Impact factor: 4.375

Review 6.  Penfluridol as a Candidate of Drug Repurposing for Anticancer Agent.

Authors:  Nguyen Minh Tuan; Chang Hoon Lee
Journal:  Molecules       Date:  2019-10-11       Impact factor: 4.411

Review 7.  Role of Sphingosylphosphorylcholine in Tumor and Tumor Microenvironment.

Authors:  Mi Kyung Park; Chang Hoon Lee
Journal:  Cancers (Basel)       Date:  2019-10-31       Impact factor: 6.639

Review 8.  Reversal of Epithelial-Mesenchymal Transition by Natural Anti-Inflammatory and Pro-Resolving Lipids.

Authors:  Chang Hoon Lee
Journal:  Cancers (Basel)       Date:  2019-11-21       Impact factor: 6.639

Review 9.  Role of specialized pro-resolving lipid mediators and their receptors in virus infection: a promising therapeutic strategy for SARS-CoV-2 cytokine storm.

Authors:  Chang Hoon Lee
Journal:  Arch Pharm Res       Date:  2021-01-04       Impact factor: 4.946

Review 10.  Exploring the Crosstalk between Inflammation and Epithelial-Mesenchymal Transition in Cancer.

Authors:  Indranil Chattopadhyay; Rangarao Ambati; Rohit Gundamaraju
Journal:  Mediators Inflamm       Date:  2021-06-14       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.